NCT02650999View on ClinicalTrials.gov

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 25, 2019

Study Completion Date

June 12, 2020

Conditions
CD19+ Diffuse Large B-cell LymphomasFollicular LymphomasMantle Cell Lymphomas
Interventions
DRUG

Pembrolizumab

200mg intravenously (IV)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02650999 - Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas | Biotech Hunter | Biotech Hunter